HK1246349A1 - 新型抗人ngf抗體fab片段 - Google Patents

新型抗人ngf抗體fab片段

Info

Publication number
HK1246349A1
HK1246349A1 HK18105725.1A HK18105725A HK1246349A1 HK 1246349 A1 HK1246349 A1 HK 1246349A1 HK 18105725 A HK18105725 A HK 18105725A HK 1246349 A1 HK1246349 A1 HK 1246349A1
Authority
HK
Hong Kong
Prior art keywords
fab fragment
novel anti
antibody fab
ngf antibody
human ngf
Prior art date
Application number
HK18105725.1A
Other languages
English (en)
Inventor
Tanaka Hirotsugu
Fujita Hirotada
Aoki Toshiaki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of HK1246349A1 publication Critical patent/HK1246349A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18105725.1A 2015-05-22 2018-05-03 新型抗人ngf抗體fab片段 HK1246349A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015104806 2015-05-22
PCT/JP2016/065099 WO2016190263A1 (ja) 2015-05-22 2016-05-20 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント

Publications (1)

Publication Number Publication Date
HK1246349A1 true HK1246349A1 (zh) 2018-09-07

Family

ID=57393503

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105725.1A HK1246349A1 (zh) 2015-05-22 2018-05-03 新型抗人ngf抗體fab片段

Country Status (22)

Country Link
US (1) US11260124B2 (zh)
EP (1) EP3299461B1 (zh)
JP (1) JP6700620B2 (zh)
KR (1) KR102440054B1 (zh)
CN (1) CN107614683B (zh)
AR (1) AR104721A1 (zh)
AU (1) AU2016268625B2 (zh)
BR (1) BR112017025029A2 (zh)
CA (1) CA2986210C (zh)
CO (1) CO2017012397A2 (zh)
HK (1) HK1246349A1 (zh)
IL (1) IL255832B (zh)
MA (1) MA42138A (zh)
MX (1) MX2017014911A (zh)
MY (1) MY184164A (zh)
PH (1) PH12017502126A1 (zh)
RU (1) RU2729825C2 (zh)
SG (1) SG11201709589XA (zh)
TW (1) TWI706959B (zh)
UA (1) UA123209C2 (zh)
WO (1) WO2016190263A1 (zh)
ZA (1) ZA201708169B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2017890B1 (nl) * 2016-11-29 2018-06-11 Josh Ip Iii B V Medische transportinrichting, hulpaandrijving, en werkwijze voor het transporteren van een dergelijke transportinrichting
EP3795176A4 (en) * 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527358A (en) 1994-01-21 1996-06-18 Medtronic, Inc. Temporary medical electrical lead
AU2003284010A1 (en) 2002-10-04 2004-05-04 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
SI1575517T1 (sl) 2002-12-24 2012-06-29 Rinat Neuroscience Corp Protitelesa proti ĺ˝iväśnemu rastnemu dejavniku in metode njihove uporabe
MXPA06000583A (es) 2003-07-15 2006-03-30 Amgen Inc Anticuerpos neutralizantes anti-ngf humano como inhibidores selectivos de la via del ngf.
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ES2338344T3 (es) * 2004-04-07 2010-05-06 Rinat Neuroscience Corporation Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
BRPI0606933B8 (pt) * 2005-01-24 2021-05-25 Cambridge Antibody Tech Limited membro de ligação específico isolado para fator de crescimento de nervos, molécula de anticorpo isolado, composição e uso de um membro de ligação específico
US9532943B2 (en) 2010-12-20 2017-01-03 Cormatrix Cardiovascular, Inc. Drug eluting patch for the treatment of localized tissue disease or defect
JP2007244601A (ja) 2006-03-15 2007-09-27 Kanazawa Univ 心筋用パッド
SI2187964T1 (sl) 2007-08-10 2015-01-30 Regeneron Pharmaceuticals, Inc. Visokoafinitetna humana protitelesa proti humanemu živčnemu rastnemu faktorju
JP4885308B2 (ja) 2009-03-19 2012-02-29 中外製薬株式会社 改良された抗体分子を含有する製剤
SG175436A1 (en) 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
SG10201510484YA (en) 2010-12-20 2016-01-28 Cormatrix Cardiovascular Inc A drug eluting patch for the treatment of localized tissue disease or defect
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
WO2012153123A1 (en) * 2011-05-06 2012-11-15 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
US9328164B2 (en) * 2011-05-06 2016-05-03 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
BR112014002576B1 (pt) * 2011-08-11 2022-08-23 Astellas Pharma Inc. Fragmento fab de anticorpo anti-ngf humano, método para produzir o mesmo e vetor de expressão compreendendo um polinucleotídeo que codifica o dito fragmento fab'
AP2014008145A0 (en) 2012-06-08 2014-12-31 Glenmark Pharmaceuticals Sa Humanized anti-trkA antibodies with animo acid substitutions
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) * 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP6651523B2 (ja) 2014-12-17 2020-02-19 ダウ グローバル テクノロジーズ エルエルシー 水性ポリマー分散物を有する粘弾性ポリウレタンフォーム

Also Published As

Publication number Publication date
US20180147281A1 (en) 2018-05-31
MA42138A (fr) 2018-03-28
IL255832B (en) 2021-07-29
BR112017025029A2 (pt) 2018-08-07
KR102440054B1 (ko) 2022-09-06
PH12017502126A1 (en) 2018-05-07
KR20180006391A (ko) 2018-01-17
CN107614683A (zh) 2018-01-19
JPWO2016190263A1 (ja) 2018-04-12
RU2017145071A (ru) 2019-06-24
CO2017012397A2 (es) 2018-02-28
TWI706959B (zh) 2020-10-11
CA2986210C (en) 2022-04-26
CN107614683B (zh) 2020-12-22
RU2017145071A3 (zh) 2019-10-17
ZA201708169B (en) 2019-06-26
US11260124B2 (en) 2022-03-01
AU2016268625A1 (en) 2017-12-07
MX2017014911A (es) 2018-03-23
RU2729825C2 (ru) 2020-08-12
IL255832A (en) 2018-01-31
WO2016190263A1 (ja) 2016-12-01
AU2016268625B2 (en) 2022-01-27
UA123209C2 (uk) 2021-03-03
AR104721A1 (es) 2017-08-09
JP6700620B2 (ja) 2020-05-27
CA2986210A1 (en) 2016-12-01
EP3299461A4 (en) 2018-12-19
SG11201709589XA (en) 2017-12-28
TW201713691A (zh) 2017-04-16
EP3299461A1 (en) 2018-03-28
EP3299461B1 (en) 2023-03-29
MY184164A (en) 2021-03-24

Similar Documents

Publication Publication Date Title
ZA201803874B (en) Humanized anti-cd73 antibodies
HK1257164A1 (zh) 新型抗pd-l1抗體
IL255727A (en) Novel anti-pd-l1 antibodies
HK1258375A1 (zh) 人源化抗-cll-1抗體
HK1251483A1 (zh) 人源化親和力成熟的抗fcrn抗體
EP3294766C0 (en) HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3
IL256579A (en) Human antibodies
IL262776A (en) Human anti-il-1r3 antibodies
ZA201903896B (en) Novel anti-human muc1 antibody fab fragment
IL254514B (en) Anti-human notch4 antibody
EP3103811A4 (en) Anti-tissue factor monoclonal antibody
ZA202000219B (en) Novel anti-human ceacam5 antibody fab fragment
IL240008A0 (en) A humanized antibody against hmgb1 or an antigen-binding fragment thereof
IL250404A0 (en) A new anti-igbeta antibody of human origin
PT3116908T (pt) Anticorpos kir3dl2 humanizados
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
HK1246349A1 (zh) 新型抗人ngf抗體fab片段
GB201511196D0 (en) Monoclonal antibodies
GB201620276D0 (en) Anti-AFB1 Fab antibody